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ABSTRACT
Background and Objectives: We aim to explore the additional discriminative accuracy of a 
deep learning (DL) algorithm using repeated-measures data for identifying people at high 
risk for cardiovascular disease (CVD), compared to Cox hazard regression.
Methods: Two CVD prediction models were developed from National Health Insurance 
Service-Health Screening Cohort (NHIS-HEALS): a Cox regression model and a DL model. 
Performance of each model was assessed in the internal and 2 external validation cohorts 
in Koreans (National Health Insurance Service-National Sample Cohort; NHIS-NSC) and in 
Europeans (Rotterdam Study). A total of 412,030 adults in the NHIS-HEALS; 178,875 adults 
in the NHIS-NSC; and the 4,296 adults in Rotterdam Study were included.
Results: Mean ages was 52 years (46% women) and there were 25,777 events (6.3%) in 
NHIS-HEALS during the follow-up. In internal validation, the DL approach demonstrated a 
C-statistic of 0.896 (95% confidence interval, 0.886–0.907) in men and 0.921 (0.908–0.934) 
in women and improved reclassification compared with Cox regression (net reclassification 
index [NRI], 24.8% in men, 29.0% in women). In external validation with NHIS-NSC, 
DL demonstrated a C-statistic of 0.868 (0.860–0.876) in men and 0.889 (0.876–0.898) in 
women, and improved reclassification compared with Cox regression (NRI, 24.9% in men, 
26.2% in women). In external validation applied to the Rotterdam Study, DL demonstrated a 
C-statistic of 0.860 (0.824–0.897) in men and 0.867 (0.830–0.903) in women, and improved 
reclassification compared with Cox regression (NRI, 36.9% in men, 31.8% in women).
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INTRODUCTION
As clustering of risk factors are associated with development of cardiovascular disease 
(CVD), various prediction models have been developed to identify high-risk individuals 
for CVD. Traditional approaches for CVD prediction models have been used Cox hazard 
regression-based analyses.1-3) These models identify risk factors in terms of odds or hazard 
ratios and then provide 10-year risks for CVD, which enables treatment strategies tailored to 
an individual.4)
Hazard regression-based models use pre-specified risk factors, which must meet the 
assumption of independence between predictors.4) In a prospective cohort, because pre-
selected risk factors are measured at pre-planned time points, the collected risk factor 
information can be fully exploited by statistical methods. However, in clinical practice, as 
types and cycles of risk factor measurement vary widely, conventional statistical models 
cannot use all of the available risk information but use only a part of such database. The 
modern hospital information system (HIS) has generated a complex, time-series digitalized 
health dataset. However, the proper analytic method has not been clearly defined to 
maximize predictive performance using these numerous, repeated-measures datasets.
Deep learning is a class of machine learning algorithms5) and demonstrates excellent 
performance in classification. The overall transformations have multiple layers in deep 
learning4) and this capacity could enhance predictive model performance in complex time-
varying datasets. To date, several small studies have explored the potential of deep learning 
for disease prediction based on data from specific time points.6-8) The purpose of this study 
was to evaluate the discriminative accuracy of a deep learning-based prediction algorithm to 
integrate repeated-measures health examination data for prediction of CVD, and to compare 
it with conventional Cox hazard regression analysis.
METHODS
This study was approved and exempted from informed consent by the Institutional Review 
Board of Yonsei University, Severance Hospital in Seoul, Korea (IRB No.4-2016-0383). This 
study used National Health Insurance Service-Health Screening Cohort (NHIS-HEALS)9) data 
and National Health Insurance Service-National Sample Cohort (NHIS-NCS)10) data derived 
from a national health screening program and the national health insurance claim database 
in South Korea and prospective cohort data from the Rotterdam Study.11) Data in NHIS-
HEALS and NHIS-NCS were fully anonymized for all analyses and informed consent was not 
specifically obtained from each participant. In the Rotterdam Study, all data were collected 
in a standardized manner according to the pre-determined study protocol and informed 
consent was obtained from all participants.
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Study population for development and internal validation
The National Health Insurance Service (NHIS) provides insurance benefits and free health 
screening programs for all citizens and residents of Korea. All adults over 40 years old are 
recommended to undergo periodic health examinations and the participation rate was as 
high as 74.8% in 2014.12) The NHIS constructed the NHIS-HEALS cohort consisting of data 
for 514,795 people (age 40–79 years), who had been randomly sampled from 10% of the 
source population who had undergone the NHIS health examination in 2002 or 2003. The 
cohort was followed up till either a participant's disqualification from health services or the 
end of the study period in 2013. Individuals who were free from CVD at baseline and had 
health examinations at least 2 times during follow-up period were included in the analysis.
Allocation of study datasets for model development
The study population in NHIS-HEALS was randomly divided into 3 groups—development, 
calibration, and validation datasets. The development dataset was used to build a model 
for fitting the parameters of the predictors; the calibration dataset was used to tune the 
parameters to prevent over-fitting in the training model; and the validation dataset was used 
to evaluate the prediction performance of the developed model. For improving predictive 
accuracy of the deep learning algorithm, the imbalance between those with CVD and without 
CVD was adjusted by under-sampling of the majority class. That is, those with and without 
CVD were constituted with a ratio of 1:1 for the development and calibration datasets to build 
a model, which has been traditionally applied in deep learning methods for dealing with 
imbalanced data, because predictive accuracy is impaired when data are imbalanced.13)
Study population for external validation
We validated the prediction models in 2 external cohorts, the NHIS-NSC and the Rotterdam 
Study. The NHIS-NSC is a national sample cohort representing all Korean age groups, in 
which 10% of the entire Koreans with health insurance were randomly sampled and followed 
up from 2002 until 2013. A subgroup of those aged between 40 and 79 years was used for 
external validation. Since the Rotterdam Study consists almost exclusively of Caucasian 
subjects, it is ethnically and geographically different from NHIS-HEALS (Supplementary 
Data 1 for the details of the Rotterdam Study). For external validation, individuals who were 
free from CVD at baseline and had health examinations at least two times were enrolled 
according to the same criteria for the development cohort.
Outcomes
The primary outcome was defined as the occurrence of one of the following events 
during the follow-up period after the baseline health examination: 1) death from CVD 
(International Classification of Diseases 10th edition [ICD-10] codes I-00 to I-99), 2) records 
of hospitalization due to myocardial infarction, coronary arterial intervention or bypass 
surgery, and 3) records of hospitalization due to stroke.
Risk predictors used in model building
To develop the risk model, an a priori decision which assumed the following variables; age, body 
mass index (BMI), systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol 
(TC), fasting plasma glucose (FPG), current smoking, and exercise - as predictor variables was 
made. Methods for risk factor measure are shown in Supplementary Data 2. Details of variables 
included in Cox regression and deep learning are described in Supplementary Table 1. Variables 
with missing data less than 4% were included in the analysis. Multiple imputation by fully 
conditional specification was used in cases where the data was missing.
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Development of prediction models
As it has been known that significant differences existed in the relations between risk factors 
and CVD occurrence according to gender, CVD prediction models were developed separately 
for men and women. Data from baseline health examination and repeated measurements 
in periodic follow-up examinations were used to build prediction models. The time to event 
was defined as the time between the date of the first health examination and that of the first 
diagnosis of an event.
The Cox proportional hazard regression model was used to develop the statistical risk 
prediction model. Cox regression model used the mean, minimum and maximum values 
and standard deviations (SDs) for continuous variables and the mean and SDs for categorical 
variables, which were calculated from the periodic health screening data. Detailed method 
for this Cox model using longitudinal data and its improved accuracy over single-measure 
method has been described previously.14)
For the deep learning algorithm, a Recurrent Neural Network-Long Short-Term Memory 
(RNN-LSTM)15) network was used. Deep learning algorithm was constituted by using the 
same variables used in Cox regression model with longitudinal data. This study used the 
methods combining survival analysis and deep learning for comparison of the performances 
between Cox hazard regression and deep learning. Some recent studies proposed replacing 
the linear part βTx in f(x) with nonlinear deep learning neural network analyses in Cox hazard 
regression.16) In these studies, they proved that the methods combining two algorithms 
worked well in standard linear function like Cox regression but also as well in the nonlinear 
settings like deep learning, Thus, this study also presented the results by replacing the 
exponential part βTx in f(x) of Cox regression with nonlinear deep learning so that it could 
make survival prediction from NHIS-HEALS sequential cohort data. The details of deep 
learning and model building process are demonstrated in Supplementary Data 3, and the 
significance of included variables are shown in Supplementary Table 2.
Evaluation of prediction performance
The prediction performance of each prediction model were evaluated in the internal 
and external validation cohorts. Model discrimination was quantified by calculating 
C-statistics for the survival model. Reclassification performance was also evaluated using 
a reclassification table and the net reclassification improvement (NRI) index between Cox 
regression and deep learning model. For calculation of NRI, 3 CVD risk categories were used; 
<10%, 10% to <20%, and ≥20% in 10 years. Model calibration was assessed by comparing 
observed and predicted event probabilities. Observed and predicted risks were compared 
by plotting 2 CVD event occurrence probabilities and indicated the Hosmer-Lemeshow χ2 
statistics and Brier score which are a measure of the fit of the model. All statistical analyses 
were conducted with SAS (version 9.4; SAS Inc., Cary, NC, USA) and the R Statistical Package 
(www.R-project.org). The statistical significance criterion was set at 2-sided p<0.05.
RESULTS
Of the original 514,866 individuals in NHIS-HEALS, those with histories of CVD according 
to their questionnaires, those who had records of CVD diagnosis at baseline, or those who 
received health examinations less than 2 times were excluded. The remaining 412,030 
individuals constituted study population for model development and internal validation.
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The individuals were divided into those with CVD (25,777 individuals, 6.3%) and those 
without CVD (386,253 individuals, 93.7%) at any point during the follow-up period thereafter.
In individuals with CVD, they were randomly allocated to the development, calibration and 
validation dataset with a ratio of 6:2:2 (15,466, 5,156, and 5,155 individuals, respectively). The 
number of individuals with and without CVD were allocated in a ratio of 1:1 in development 
and calibration cohort. The ratio of 6.3:93.7, which reflects actual occurrence of CVD in the 
original NHIS-HEALS cohort, were used for the validation cohort. Therefore, in individuals 
without CVD, they were randomized as follows; 15,466 individual for development, 5,156 
individual for calibration, and 77,202 individuals for validation. Therefore, a total of 30,932 
individuals were used for development; 10,312 individuals for calibration; and 82,357 
individuals for validation (Figure 1). Details of the population selection process in the NHIS-
NSC and the Rotterdam Study are also described in Figure 1.
Table 1 shows baseline characteristics of development and validation datasets. External 
validation was performed in 178,875 persons (women 51.0%) in the NHIS-NSC and 4,296 
(women 50.6%) from the Rotterdam Study. Mean follow-up duration was approximately 
10 years in all 3 validation datasets. Mean number of health examinations was lower in the 
Rotterdam Study than in the NHIS-HEALS or NHIS-NSC cohorts. The cumulative CVD event 
rate was higher in the Rotterdam Study (11.7%) than in the NHIS-HEALS (6.3%) and NHIS-
NSC (5.2%).
Relative risk estimates for the Cox model predictors were described in Supplementary Table 3. 
Age, BMI, DBP, current smoking and exercise were associated with CVD in men while age, SBP, 
TC and exercise were associated with CVD in women. Moreover, SDs of CVD risk factors were 
more important compared to their mean values in Cox models using repeated measures.
Performance indicators of each model are demonstrated in Tables 2 and 3. C-statistics (95% 
confidence interval [CI]) for Cox regression and deep learning were 0.813 (0.803–0.823) and 
0.896 (0.886–0.907) in men and 0.837 (0.825–0.849) and 0.921 (0.908–0.934) in women in 
the internal validation dataset, suggesting improved performance from Cox regression to 
deep learning. From Cox regression to deep learning, the NRI was 24.8% (p<0.001) in men 
and 29.0% (p<0.001) in women. In external validation with NHIS-NSC (External validation 
1), deep learning had a C-statics of 0.868 (95% CI, 0.86–0.88) in men and 0.889 (0.88–0.91) 
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Table 1. Baseline characteristics of the development, internal validation and external validation cohorts
Variable Development Internal validation External validation 1 External validation 2
Men (n=18,009) Women (n=12,923) Men (n=44,694) Women (n=37,663) Men (n=87,687) Women (n=91,188) Men (n=1,686) Women (n=2,610)
Age (years) 54.6±9.9 56.3±10.2 51.3±8.9 52.7±9.3 49.4±8.8 49.9±9.1 66.2±6.2 66.7±6.3
Hypertension 6,094 (25.6) 5,594 (31.6) 7,468 (16.7) 7,725 (20.5) 13,685 (15.6) 16,491 (18.1) 1,073 (63.6) 1,670 (64.0)
Diabetes 2,926 (12.3) 1,684 (9.5) 3,774 (8.4) 2,019 (5.4) 8,071 (9.2) 5,089 (5.6) 185 (11.0) 236 (9.0)
Smoking 8,126 (45.1) 418 (3.2) 19,300 (43.2) 1,005 (2.7) 39,748 (45.3) 2,893 (3.2) 400 (23.7) 469 (18.0)
Exercise 8,712 (48.4) 3,985 (30.8) 22,782 (51.0) 12,520 (33.2) 43,614 (49.7) 33,651 (36.9) 1,286 (76.3) 1,934 (74.1)
BMI (kg/m2) 24.0±2.9 24.1±3.1 24.0±2.9 23.9±3.1 24.0±2.9 23.9±3.1 26.7±3.3 27.3±4.4
SBP (mmHg) 131.2±18.2 127.7±19.5 128.1±17.1 124.2±18.5 128.3±17.2 124.5±18.1 142.8±20.7 140.7±20.6
DBP (mmHg) 82.4±11.7 78.8±12.0 81.1±11.4 77.2±11.7 80.8±11.2 77.2±11.4 79.3±11.1 76.1±10.4
FPG (mg/dL) 103.1±40.3 100.1±43.5 99.5±35.9 95.0±30.7 100.5±33.9 95.5±27.8 107.1±25.4 103.9±23.3
TC (mg/dL) 200.6±39.6 205.4±40.2 198.8±38.0 201.9±39.5 198.2±37.9 202.3±38.3 218.9±36.5 233.5±35.6
Follow-up (years) 8.5±2.8 8.9±2.6 10.3±1.7 10.4±1.4 9.6±2.9 9.3±2.2 10.9±2.3 11.4±2.2
No. of health screening 5.0±2.7 4.4±2.0 6.1±2.9 5.2±2.1 5.2±2.7 4.4±1.9 2.9±0.5 2.6±0.5
BMI = body mass index; DBP = diastolic blood pressure; FPG = fasting plasma glucose; SBP = systolic blood pressure; TC = total cholesterol.
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in women and improved reclassification compared with Cox regression (NRI, 24.9% in 
men, 26.2% in women, all p<0.001). In external validation with Rotterdam Study (External 
validation 2), deep learning had a C-statics of 0.860 (95% CI, 0.82–0.90) in men and 0.867 
(0.83–0.90) in women and improved reclassification compared with Cox regression (NRI, 
36.9% in men, 31.8% in women, all p<0.001).
The Brier scores in each deep learning model indicated good calibration between the 
estimated predicted risk and observed risk (Tables 2 and 3). A calibration plots for deep 
learning models also confirmed good agreement between the estimated predicted risk and 
observed risk, grouped by decile of risk (Figure 2).
DISCUSSION
The principal findings of this study were as follows: 1) A deep learning algorithm significantly 
improved predictive performance over the conventional statistical approach when analyzing 
a large repeated-measures data for prediction of CVD. 2) Better performance of the deep 
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Table 2. Predictive performance of FRS and prediction models of men in internal and external validation cohorts
Statistics
Men
Internal validation External validation 1 External validation 2
Cox regression Deep learning Cox regression Deep learning Cox regression Deep learning
C-statistic (95% CI) 0.813 (0.803–0.823) 0.896 (0.886–0.907) 0.801 (0.793–0.809) 0.868 (0.860–0.876) 0.779 (0.742–0.816) 0.860 (0.824–0.897)
χ2 test (p value) 5.02 (0.833) 5.28 (0.809) 10.42 (0.318) 9.70 (0.375) 4.30 (0.891) 5.96 (0.744)
Brier score 0.058 0.040 0.056 0.041 0.114 0.087
Cox regression to deep learning Cox regression to deep learning Cox regression to deep learning
Difference in C-statistic (95% CI) 0.083 (0.069–0.097) 0.067 (0.055–0.079) 0.081 (0.030–0.132)
p value <0.001 <0.001 0.002
Reclassification
Cases move to higher 1,223 (39.1%) 2,195 (39.7%) 106 (42.2%)
Cases move to lower 619 (19.8%) 1,079 (19.5%) 53 (21.1%)
Controls moved to higher 2,812 (6.8%) 8,189 (10.0%) 197 (13.7%)
Controls moved to lower 5,074 (12.2%) 12,041 (14.7%) 424 (29.5%)
NRI (%) 24.76 24.88 36.93
p value <0.001 <0.001 <0.001
CI = confidence interval; FRS = Framingham risk score; NRI = net reclassification improvement.
Table 3. Predictive performance of FRS and prediction models of women in internal and external validation cohorts
Statistics
Women
Internal validation External validation 1 External validation 2
Cox regression Deep learning Cox regression Deep learning Cox regression Deep learning
C-statistic (95% CI) 0.837 (0.825–0.849) 0.921 (0.908–0.934) 0.836 (0.826–0.846) 0.889 (0.879–0.898) 0.792 (0.755–0.829) 0.867 (0.830–0.903)
χ2 test (p-value) 2.58 (0.979) 3.28 (0.952) 6.39 (0.700) 4.46 (0.879) 2.15 (0.989) 2.40 (0.984)
Brier score 0.045 0.031 0.038 0.027 0.082 0.064
Cox regression to deep learning Cox regression to deep learning Cox regression to deep learning
Difference in C-statistic (95% CI) 0.084 (0.066–0.102) 0.053 (0.039–0.067) 0.075 (0.022–0.128)
p value <0.001 <0.001 0.005
Reclassification
Cases moved to higher 837 (41.3%) 1,602 (42.4%) 110 (43.5%)
Cases moved to lower 316 (15.6%) 734 (19.4%) 49 (19.4%)
Controls moved to higher 1,437 (4.0%) 5,166 (5.9%) 201 (8.5%)
Controls moved to lower 2,604 (7.3%) 7,987 (9.1%) 383 (16.2%)
NRI (%) 29.02 26.18 31.83
p value <0.001 <0.001 <0.001
CI = confidence interval; FRS = Framingham risk score; NRI = net reclassification improvement.
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Figure 2. Predicted vs. observed probability of cardiovascular disease by deep learning in the internal validation and external validation cohorts.
learning algorithm over Cox regression analysis was confirmed by external validation in the 
Rotterdam Study, a different ethnicity, as well as in a different South Korean cohort.
Various risk prediction models have been proposed for the purpose of CVD prediction.1-3)17)18) 
However, since the accuracy of the CVD prediction models based on risk factor or statistics 
is not satisfactory in all circumstances,19) various attempts to increase the predictability are 
continuing. The most common approach is to add new biomarkers as predictors to improve 
disease predictability.20)21) However, apart from costs, biomarkers such as coronary artery 
calcium score has demonstrated only modest increase in predictive accuracy when added to a 
traditional risk factor model.22)
Since electronic health record was introduced several decades ago, huge amount of data 
has been accumulating in the medical field. In the current study, deep learning model using 
periodic risk factor measures showed better predictive accuracy over traditional Cox hazard 
regression approach. We used longitudinal Cox regression model incorporating mean and 
variability information into the Cox model, which showed better performance compared to the 
single measured method.14) Still, Cox regression demonstrated lower predictive accuracy than 
deep learning. A nationwide repeated health screening system like that used in South Korea 
may not be applicable to all health care systems. However, accumulation of large-scale data is 
accelerating in the medical field as HIS is advancing as a healthcare platform. The deep learning 
model provided good discrimination and calibration using these repeated data and can, 
therefore, may be a valuable tool for risk predictions in the era of electronic health record.
Deep learning, which have shown high value for many classification problems,23) is different 
from Cox regression-based statistics in many respects. A Cox regression model needs 
assumptions of proportional changes in the hazards being predicted and independence 
among pre-specified variables and does not reflect variable changes over time. In contrast, 
deep learning is agnostic in any assumptions and fully uses variable that are constantly 
changing into their models. Therefore, deep learning is a more proper method for analyzing 
data from daily clinical practice, where numerous confounding factors exist and risk factors 
for each individual change continuously. Moreover, the risk factors are closely related to each 
other and their interactions are complex. In the current study, traditional risk factors derived 
from prior cohort studies such as BMI and TC were not significant predictors for CVD in 
regression models, which corresponds to previous findings derived from analysis of various 
hospital data that showed many traditional risk factors were less significant factors for CVD 
occurrence.24) In this regard, deep learning may be more suitable for analyzing complex 
time-varying data derived from standard clinical practice, which may differ greatly from data 
derived from prospective controlled trials.
In both the NHIS-NSC of a different Korean population and the Rotterdam Study of a 
Europeans, deep learning approach showed improved discrimination to a considerable extent 
compared to the traditional statistical approach, implying its robust predictive power to be 
highly generalizable in geographically-disparate ethnically-diverse settings. Application of 
the developed model in this present study to other large-scale ethnic cohorts—such as blacks 
and Hispanics—now appears warranted. Models derived from machine learning, including 
deep learning, are fundamentally dynamic, and can incorporate new data for the continuous 
update and optimization of its algorithm, which improves its predictive performance over 
time.25)26) More importantly, models derived from machine learning algorithm can be locally 
retrained in diverse populations to maximize accuracy in different populations of patients 
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with varying clinical and demographic profiles.27) The paradigm shift of methodology for 
building a prediction model from traditional hypothesis-driven statistical analysis to these 
self-training deep learning methods can help offer insights for precision medicine into 
personalized disease prediction. Regarding the importance of a continuous learning system 
and informatics tools to assist health-care providers in interpreting data and tailoring 
decisions of treatment to a patient in precision medicine,28) the deep learning algorithm 
represents new opportunities for physicians to engage in precision medicine by providing 
precise information of CVD risk in each individual.
This study had several limitations. First, the level of risk factors can be modified by drug or 
non-drug treatment during the course of follow-up, thereby changing the risk of CVD, and 
these modifications may be unpredictable based upon physician and patient behavior. While 
predict models may be influenced by such confounders, it is likely to be more affected by 
single point measures. This study showed that deep learning methods can further improve 
CVD prediction ability using repeatedly-measured information, suggesting the strengths 
of deep learning for these data. Second, outcome events were ascertained from health 
insurance claims data and diagnoses were not adjudicated by medical records or laboratory 
tests as in other large data studies. However, evaluation of the deep learning approach in a 
prospectively enrolled cohort study nevertheless demonstrates the robustness of this model 
in populations in which events were prospectively ascertained. Third, some risk factors 
some risk predictors included in the prediction model did not satisfy the assumptions 
required for proportional hazard analysis (Supplementary Table 4). However, we used 
proportional hazard analysis, which has been the most widely used for CVD prediction, 
because our main purpose was to assess whether we could improve the predictive power 
of the models by using repeatedly measured data. Fourth, incorporation of more complex 
information can enhance the predictive power of deep learning, since the benefit of deep 
learning is its capacity to deal with large complex data without any assumptions. However, 
since the purpose of the current study was to confirm the superior analytic performance 
of deep learning to that of Cox regression, we used the same variables for both models. 
Further studies using a large number of variables would be needed to validate predictive 
performance of deep learning with increase in number of variables. Fifth, the number of 
health screening was relatively small in Rotterdam Study compared to NHIS-HEALS and 
NHIS-NSC. This might be one of the reasons for the lower C-statistics in Rotterdam Study. 
Sixth, the problem of imbalanced data was adjusted by under-sampling of the majority class. 
Further studies with more complex validation scenario and experiments with different class 
ratios are needed.
In conclusion, a time-series deep learning algorithm analysis of periodic health screening 
data resulted in predictive models for CVD outcomes that had greater discriminative accuracy 
then conventional statistical approaches. However, the utility of this model in clinical care 
requires further research.
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